OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
August 03, 2022
Industry is adapting to the increasing complexity and poor solubility and bioavailability of molecules in the pipeline.
The purpose of this article was to demonstrate the application of a new thermogelling matrix in the healing of wounds.
Further advances in construct design and manufacturing scalability are still needed.
August 02, 2022
Bio-Rad has expanded its range of recombinant monoclonal anti-idiotypic antibodies.
The new facility in Albany, Ore., will support biopharmaceutical development and lyophilization services.
Novasep-PharmaZell will increase API production capacity at its Mourenx site with €7.3M investment.
FDA and the USPTO hope to promote competition by challenging strategies designed to block timely approval of generics and biosimilars.
Promising applications for targeted delivery may be cresting the horizon.
Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, answers some commonly asked questions about biologics license applications.
In this episode, Fernando Muzzio provides greater insight into a novel approach to improving drug solubility—continuous melt coating.